Literature DB >> 27555662

Negative regulation of NF-κB p65 activity by serine 536 phosphorylation.

Jean-Philippe Pradère1, Céline Hernandez1, Christiane Koppe2, Richard A Friedman3, Tom Luedde2, Robert F Schwabe4.   

Abstract

Nuclear factor κB (NF-κB) is a master regulator of inflammation and cell death. Whereas most of the activity of NF-κB is regulated through the inhibitor of κB (IκB) kinase (IKK)-dependent degradation of IκB, IKK also phosphorylates subunits of NF-κB. We investigated the contribution of the phosphorylation of the NF-κB subunit p65 at the IKK phosphorylation site serine 536 (Ser(536)) in humans, which is thought to be required for the activation and nuclear translocation of NF-κB. Through experiments with knock-in mice (S534A mice) expressing a mutant p65 with an alanine-to-serine substitution at position 534 (the murine homolog of human Ser(536)), we observed increased expression of NF-κB-dependent genes after injection of mice with the inflammatory stimulus lipopolysaccharide (LPS) or exposure to gamma irradiation, and the enhanced gene expression was most pronounced at late time points. Compared to wild-type mice, S534A mice displayed increased mortality after injection with LPS. Increased NF-κB signaling in the S534A mice was at least in part explained by the increased stability of the S534A p65 protein compared to that of the Ser(534)-phosphorylated wild-type protein. Together, our results suggest that Ser(534) phosphorylation of p65 in mice (and, by extension, Ser(536) phosphorylation of human p65) is not required for its nuclear translocation, but instead inhibits NF-κB signaling to prevent deleterious inflammation.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27555662      PMCID: PMC5327697          DOI: 10.1126/scisignal.aab2820

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  42 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  Regulation of transcription factor function by phosphorylation.

Authors:  A J Whitmarsh; R J Davis
Journal:  Cell Mol Life Sci       Date:  2000-08       Impact factor: 9.261

Review 3.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

Review 4.  IKK biology.

Authors:  Fei Liu; Yifeng Xia; Aaron S Parker; Inder M Verma
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

5.  IKKbeta phosphorylates p65 at S468 in transactivaton domain 2.

Authors:  Robert F Schwabe; Hiroaki Sakurai
Journal:  FASEB J       Date:  2005-07-26       Impact factor: 5.191

6.  Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain.

Authors:  M Hibi; A Lin; T Smeal; A Minden; M Karin
Journal:  Genes Dev       Date:  1993-11       Impact factor: 11.361

7.  IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide.

Authors:  Fan Yang; Eric Tang; Kunliang Guan; Cun-Yu Wang
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

8.  Helicobacter pylori CagA activates NF-kappaB by targeting TAK1 for TRAF6-mediated Lys 63 ubiquitination.

Authors:  Acacia Lamb; Xiao-Dong Yang; Ying-Hung N Tsang; Jiang-Dong Li; Hideaki Higashi; Masanori Hatakeyama; Richard M Peek; Steven R Blanke; Lin-Feng Chen
Journal:  EMBO Rep       Date:  2009-10-09       Impact factor: 8.807

9.  Human T-cell lymphotropic virus type 1 tax induction of biologically Active NF-kappaB requires IkappaB kinase-1-mediated phosphorylation of RelA/p65.

Authors:  Alison M O'Mahony; Mauricio Montano; Katrien Van Beneden; Lin-Feng Chen; Warner C Greene
Journal:  J Biol Chem       Date:  2004-02-12       Impact factor: 5.157

10.  Inhibition of RelA-Ser536 phosphorylation by a competing peptide reduces mouse liver fibrosis without blocking the innate immune response.

Authors:  Anna Moles; Ana M Sanchez; Paul S Banks; Lindsay B Murphy; Saimir Luli; Lee Borthwick; Andrew Fisher; Steven O'Reilly; Jacob M van Laar; Steven A White; Neil D Perkins; Alastair D Burt; Derek A Mann; Fiona Oakley
Journal:  Hepatology       Date:  2013-01-08       Impact factor: 17.425

View more
  35 in total

1.  Deamidation Shunts RelA from Mediating Inflammation to Aerobic Glycolysis.

Authors:  Jun Zhao; Mao Tian; Shu Zhang; Alireza Delfarah; Ruoyun Gao; Youliang Rao; Ali Can Savas; Anjie Lu; Larissa Bubb; Xiao Lei; Rosa Moshirian; Wenjie Zhu; Cheng Peng; Taijiao Jiang; Lin Chen; Nicholas A Graham; Pinghui Feng
Journal:  Cell Metab       Date:  2020-04-22       Impact factor: 27.287

2.  Indomethacin impairs mitochondrial dynamics by activating the PKCζ-p38-DRP1 pathway and inducing apoptosis in gastric cancer and normal mucosal cells.

Authors:  Somnath Mazumder; Rudranil De; Subhashis Debsharma; Samik Bindu; Pallab Maity; Souvik Sarkar; Shubhra Jyoti Saha; Asim Azhar Siddiqui; Chinmoy Banerjee; Shiladitya Nag; Debanjan Saha; Saikat Pramanik; Kalyan Mitra; Uday Bandyopadhyay
Journal:  J Biol Chem       Date:  2019-04-02       Impact factor: 5.157

3.  Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.

Authors:  Tomasz Sewastianik; Maria Luisa Guerrera; Keith Adler; Peter S Dennis; Kyle Wright; Vignesh Shanmugam; Ying Huang; Helen Tanton; Meng Jiang; Amanda Kofides; Maria G Demos; Audrey Dalgarno; Neil A Patel; Anwesha Nag; Geraldine S Pinkus; Guang Yang; Zachary R Hunter; Petr Jarolim; Nikhil C Munshi; Steven P Treon; Ruben D Carrasco
Journal:  Blood Adv       Date:  2019-11-12

4.  A Map of Human Mitochondrial Protein Interactions Linked to Neurodegeneration Reveals New Mechanisms of Redox Homeostasis and NF-κB Signaling.

Authors:  Ramy H Malty; Hiroyuki Aoki; Ashwani Kumar; Sadhna Phanse; Shahreen Amin; Qingzhou Zhang; Zoran Minic; Florian Goebels; Gabriel Musso; Zhuoran Wu; Hosam Abou-Tok; Michael Meyer; Viktor Deineko; Sandy Kassir; Vishaldeep Sidhu; Matthew Jessulat; Nichollas E Scott; Xuejian Xiong; James Vlasblom; Bhanu Prasad; Leonard J Foster; Tiziana Alberio; Barbara Garavaglia; Haiyuan Yu; Gary D Bader; Ken Nakamura; John Parkinson; Mohan Babu
Journal:  Cell Syst       Date:  2017-11-08       Impact factor: 10.304

5.  NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells.

Authors:  Bruna Alves Fenerich; Jaqueline Cristina Fernandes; Ana Paula Nunes Rodrigues Alves; Juan Luiz Coelho-Silva; Renata Scopim-Ribeiro; Priscila Santos Scheucher; Christopher A Eide; Cristina E Tognon; Brian J Druker; Eduardo Magalhães Rego; João Agostinho Machado-Neto; Fabiola Traina
Journal:  Signal Transduct Target Ther       Date:  2020-01-24

6.  Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle.

Authors:  David W Hammers; Margaret M Sleeper; Sean C Forbes; Cora C Coker; Michael R Jirousek; Michael Zimmer; Glenn A Walter; H Lee Sweeney
Journal:  JCI Insight       Date:  2016-12-22

Review 7.  GSK-3: a multifaceted player in acute leukemias.

Authors:  Alberto M Martelli; Camilla Evangelisti; Francesca Paganelli; Francesca Chiarini; James A McCubrey
Journal:  Leukemia       Date:  2021-04-02       Impact factor: 11.528

8.  Tranilast induces MiR-200c expression through blockade of RelA/p65 activity in leiomyoma smooth muscle cells.

Authors:  Tsai-Der Chuang; Amit Rehan; Omid Khorram
Journal:  Fertil Steril       Date:  2020-03-18       Impact factor: 7.329

Review 9.  Targeting IκappaB kinases for cancer therapy.

Authors:  Nikee Awasthee; Vipin Rai; Srinivas Chava; Palanisamy Nallasamy; Ajaikumar B Kunnumakkara; Anupam Bishayee; Subhash C Chauhan; Kishore B Challagundla; Subash C Gupta
Journal:  Semin Cancer Biol       Date:  2018-02-24       Impact factor: 15.707

10.  Inhibitory feedback control of NF-κB signalling in health and disease.

Authors:  Jack A Prescott; Jennifer P Mitchell; Simon J Cook
Journal:  Biochem J       Date:  2021-07-16       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.